Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator.

Fabian CJ, Kimler BF, Anderson J, Tawfik OW, Mayo MS, Burak WE Jr, O'Shaughnessy JA, Albain KS, Hyams DM, Budd GT, Ganz PA, Sauter ER, Beenken SW, Grizzle WE, Fruehauf JP, Arneson DW, Bacus JW, Lagios MD, Johnson KA, Browne D.

Clin Cancer Res. 2004 Aug 15;10(16):5403-17.

2.

Beyond tamoxifen new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention.

Fabian CJ, Kimler BF.

Ann N Y Acad Sci. 2001 Dec;952:44-59. Review.

PMID:
11795443
3.

Arzoxifene as therapy for endometrial cancer.

Burke TW, Walker CL.

Gynecol Oncol. 2003 Aug;90(2 Pt 2):S40-6. Review.

PMID:
12928005
4.

Arzoxifene: a promising new selective estrogen receptor modulator for clinical chemoprevention of breast cancer.

Sporn MB.

Clin Cancer Res. 2004 Aug 15;10(16):5313-5. Review. No abstract available.

5.

Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.

Lee WL, Chao HT, Cheng MH, Wang PH.

Maturitas. 2008 Jun 20;60(2):92-107. doi: 10.1016/j.maturitas.2008.04.009. Epub 2008 Jun 4. Review.

PMID:
18534794
6.

Clinical trials with retinoids for breast cancer chemoprevention.

Zanardi S, Serrano D, Argusti A, Barile M, Puntoni M, Decensi A.

Endocr Relat Cancer. 2006 Mar;13(1):51-68. Review.

7.

Arzoxifene: the development and clinical outcome of an ideal SERM.

Munster PN.

Expert Opin Investig Drugs. 2006 Mar;15(3):317-26. Review.

PMID:
16503767
8.

Raloxifene in breast cancer prevention.

Gennari L, Merlotti D, Paola VD, Nuti R.

Expert Opin Drug Saf. 2008 May;7(3):259-70. doi: 10.1517/14740338.7.3.259 . Review.

PMID:
18462184
9.

SERMs in chemoprevention of breast cancer.

Gasco M, Argusti A, Bonanni B, Decensi A.

Eur J Cancer. 2005 Sep;41(13):1980-9. Review.

PMID:
15964182
10.

Selective modulation of postmenopausal women: cutting the Gordian knot of hormone replacement therapy with breast carcinoma.

Diamanti-Kandarakis E, Sykiotis GP, Papavassiliou AG.

Cancer. 2003 Jan 1;97(1):12-20. Review.

11.

Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.

Robertson JF.

Cancer Treat Rev. 2004 Dec;30(8):695-706. Review.

PMID:
15541579
12.

Chemoprevention in postmenopausal women.

Rastogi P.

Menopause. 2008 Jul-Aug;15(4 Suppl):810-5. doi: 10.1097/gme.0b013e318178863e. Review.

PMID:
18596603
13.

Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators.

Dunn BK, Ryan A.

Ann N Y Acad Sci. 2009 Feb;1155:141-61. doi: 10.1111/j.1749-6632.2009.03688.x. Review.

PMID:
19250201
14.
15.
16.

Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.

Ganz PA, Land SR.

Menopause. 2008 Jul-Aug;15(4 Suppl):797-803. doi: 10.1097/gme.0b013e31817be9af. Review.

PMID:
18596601
17.

Chemoprevention of breast cancer.

Castrellon AB, Gl├╝ck S.

Expert Rev Anticancer Ther. 2008 Mar;8(3):443-52. doi: 10.1586/14737140.8.3.443. Review.

PMID:
18366291
18.

Risks and benefits of therapy with menopausal hormones versus selective estrogen-receptor modulators in peri- and postmenopausal women at increased breast cancer risk.

Col NF, Chlebowski RT.

Menopause. 2008 Jul-Aug;15(4 Suppl):804-9. doi: 10.1097/gme.0b013e31817e5cce. Review.

PMID:
18596602
19.

Breast cancer risk with postmenopausal hormonal treatment.

Collins JA, Blake JM, Crosignani PG.

Hum Reprod Update. 2005 Nov-Dec;11(6):545-60. Epub 2005 Sep 8. Review. Erratum in: Hum Reprod Update. 2006 May-Jun;12(3):331.

PMID:
16150813
20.

[Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].

Maeda T, Ke HZ, Simmons H, Thompson D.

Clin Calcium. 2004 Oct;14(10):85-93. Review. Japanese.

PMID:
15577137

Supplemental Content

Support Center